TY - THES 
TI - Análisis de impacto presupuestal de Canakinumab y Etanercept en el tratamiento de artritis isiopatica juvenil en Colombia 2017
AU - Hurtado Rivera, María Cristina
AU - Pinto Manrique, Yurany Lizeth
AB - Juvenile Idiopathic Arthritis is a chronic disease with progressive deterioration, which occurs in children between 2 to 17 years, its pathogenesis is still unknown and is considered to have an prevalence of 86-94 cases per million children and an incidence from 6 to 10 case per 100,000 children; Given the nature of juvenile idiopathic arthritis disease, its impact on health, economy, population and access to treatments for it is an important objective and challenge for public health. In Colombia there is a management guide for Juvenile Idiopathic Arthritis in which the first-choice drugs are considered, as well as biologic therapy with the drug Etanercept and biotechnology, such as Cankinumab, the latter not included in the basic plan of care. This budget impact analysis, presented in two scenarios in a period of three consecutive years, becomes important since, if feasible, it suggests the inclusion of a new health technology in the basic plan, the improvement in the quality of life of the patients and the affordability of this.
DA - 2019
KW - Artritis juvenil - Tratamiento con drogas
KW - Artritis juvenil - Tratamiento con drogas
KW - Artritis juvenil - Tratamiento con drogas
KW - Artritis juvenil - Tratamiento con drogas
PB - Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019
UR - https://repository.udca.edu.co/handle/11158/1368
ER -